Search

everythinglearnresearchcommunity

for

Search:↓

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

User "mo_movic" shared 4-month progress using finasteride, minoxidil, ketoconazole, and dermaroller for hair loss. Others congratulated and discussed their own experiences, with "mo_movic" reducing finasteride dose and using ketoconazole twice a week.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

Rapamycin and metformin may have hair regeneration properties. Specific treatments discussed include Minoxidil, finasteride, and RU58841.

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

Kintor Pyrilutamide treatment, a potential hair loss treatment that may become available to the public soon. People have been experimenting with using it in topical form, with mixed results and no reported side effects.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

Taking 5mg oral minoxidil at night instead of splitting 2.5mg doses, with the rationale that a single larger dose may provide a stronger activation for hair follicles and reduce peak-related side effects. Some users report sleep issues with nighttime dosing, while others find it beneficial; opinions on effectiveness and side effects vary.

A 30-year-old considering a hair transplant has been using treatments like oral Minoxidil, Dutasteride, topical Minoxidil, copper peptide serum, red light laser therapy, microneedling, and vitamin therapy for hair loss. They are advised that a hair transplant is still an option, but maintaining current treatments is crucial to support the transplant and prevent further hair loss.

A user reported that after experiencing hair thinning, they started using finasteride in 2024 and later began GHK-Cu peptide injections in March 2026, which they believe stopped their hair loss and made their hair feel thicker. The user shared their experience despite receiving criticism for not solely endorsing finasteride.

A 20-year-old male experiencing hair loss is using topical finasteride and recently added dutasteride but is still losing hair and considering giving up. Suggestions include being patient, giving dutasteride more time, trying oral finasteride, adding minoxidil, and considering other treatments like low-level laser therapy.

A 27-year-old male shared his positive experience using finasteride and minoxidil for hair regrowth over a year, noting initial shedding but no significant side effects. He emphasized the effectiveness of combining these treatments and advised others to consult doctors and be patient with the process.

Taking creatine does not affect the effectiveness of finasteride for hair loss. Users generally agree that creatine is safe to use alongside finasteride and minoxidil.

The conversation is about whether vellus hair should be included in hair fall counts, with data showing daily hair loss. The consensus is that shedding, including vellus hair, is normal and within physiological limits.

COVID and COVID vaccination can trigger hair loss, primarily telogen effluvium, due to stress and immune system activation. Proper diagnosis and addressing factors like nutrition and stress are crucial for recovery.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.

The user has been using finasteride for over a year and noticed short, prickly hairs on their scalp that don't grow like the rest of their hair. Despite losing about 40 short hairs when washing, their overall hair density hasn't decreased.

The user has been taking Finasteride for almost 2 months and using Minoxidil 5% spray daily since March. They feel Minoxidil hasn't helped after 7 months, and Finasteride has increased hair loss.

Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.

Peptides like GHK-Cu are discussed for hair regrowth, with mixed results; some users report no regrowth, while others notice thicker hair. Topical application is common, and proper sourcing and mixing are emphasized.

A 23-year-old male experienced initial success with finasteride, topical minoxidil, and ketoconazole for hair loss, but persistent shedding and scalp issues led him to switch to dutasteride without improvement. Users suggest stress management, addressing potential seborrheic dermatitis, and patience with the treatment process.

After 8 months of using oral Minoxidil 5mg and Finasteride 1mg, the user still experiences hair loss, particularly miniaturized hairs in the mid-scalp area, along with itching. They are concerned about losing around 40 hairs daily despite treatment.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.